Alectinib

Alectinib Reactions 1680, p21 - 2 Dec 2017 Acquired resistance to alectinib during treatment of AKK-positive lung tumour: case report A 51-year-old man had acquired resistance to alectinib treatment of during AKK-positive lung tumour with alectinib [dosage and route not stated]. The man, who had AKK-positive lung tumour, was started on first-line treatment with alectinib. However, he acquired resistance to alectinib in three months. Subsequently, the man was started on ceritinib or crizotinib, which showed only a moderate and temporary effect. Later, he died of unspecified reasons [outcome of reaction not stated]. Author comment: "However, acquired resistance to alectinib is inevitable" "The lung tumors acquired resistance to first-line treatment of alectinib in three months" Makimoto G, et al. A comprehensive analysis of autopsied specimens and patient derived cell lines in ALK-positive lung cancers with rapid acquired resistance to alectinib. Cancer Research 77 (Suppl. 13): abstr. 3164, Jul 2017. Available from: URL: http://doi.org/10.1158/1538-7445.AM2017-3164 [abstract] - Japan 803284842 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Alectinib

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/alectinib-P9RR20PMOi
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-38952-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p21 - 2 Dec 2017 Acquired resistance to alectinib during treatment of AKK-positive lung tumour: case report A 51-year-old man had acquired resistance to alectinib treatment of during AKK-positive lung tumour with alectinib [dosage and route not stated]. The man, who had AKK-positive lung tumour, was started on first-line treatment with alectinib. However, he acquired resistance to alectinib in three months. Subsequently, the man was started on ceritinib or crizotinib, which showed only a moderate and temporary effect. Later, he died of unspecified reasons [outcome of reaction not stated]. Author comment: "However, acquired resistance to alectinib is inevitable" "The lung tumors acquired resistance to first-line treatment of alectinib in three months" Makimoto G, et al. A comprehensive analysis of autopsied specimens and patient derived cell lines in ALK-positive lung cancers with rapid acquired resistance to alectinib. Cancer Research 77 (Suppl. 13): abstr. 3164, Jul 2017. Available from: URL: http://doi.org/10.1158/1538-7445.AM2017-3164 [abstract] - Japan 803284842 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from Google Scholar, PubMed
Create lists to organize your research
Export lists, citations
Access to DeepDyve database
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off